Network meta-analysis of 23 trials (n=18,689) in metastatic hormone-sensitive prostate cancer: no triplet regimen significantly improved PFS or OS over ARPI + ADT; docetaxel + ARPI + ADT improved OS in high-volume disease only (HR 0.76).
Meta-analysisn = 18,689
Miyajima et al. First-Line Systemic Treatments of Metastatic Hormone-Sensitive Prostate Cancer: Updated Systematic Review and Network Meta-Analysis